{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:19Z","timestamp":1791994579785,"version":"4.4.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.588315","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T05:06:26Z","timestamp":1603775186000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris"],"prefix":"10.3389","volume":"11","author":[{"given":"Katharina","family":"Meier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzan","family":"Solimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Waschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted Therapies for Autoimmune Bullous Diseases: Current Status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: Current and Future Therapeutic Strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-005-4533-5","article-title":"Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development","volume":"62","author":"Jeon","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.06.022","article-title":"Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus","volume":"138","author":"Spindler","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1038\/s41598-017-03697-7","article-title":"Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus","volume":"7","author":"Walter","year":"2017","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.619","article-title":"PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita","volume":"136","author":"Koga","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002675","article-title":"Protective endogenous cyclic adenosine 5\u2019-monophosphate signaling triggered by pemphigus autoantibodies","volume":"185","author":"Spindler","year":"2010","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-737676","article-title":"Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies","volume":"128","author":"Cooney","year":"2016","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2018.3280","article-title":"A case of anti-laminin gamma1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast","volume":"28","author":"Waki","year":"2018","journal-title":"Eur J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01662","article-title":"Apremilast Ameliorates Experimental Arthritis via Suppression of Th1 and Th17 Cells and Enhancement of CD4(+)Foxp3(+) Regulatory T Cells Differentiation","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1186\/ar3041","article-title":"Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis","volume":"12","author":"McCann","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803310","article-title":"Inhibition of cAMP degradation improves regulatory T cell-mediated suppression","volume":"182","author":"Bopp","year":"2009","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez204","article-title":"Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis","volume":"58","author":"Mavropoulos","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148919","article-title":"Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus","volume":"11","author":"Hennerici","year":"2016","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.03.036","article-title":"Targeting inducible costimulator expressed on CXCR5(+)PD-1(+) TH cells suppresses the progression of pemphigus vulgaris","volume":"18","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3578","article-title":"Suppression by TFR cells leads to durable and selective inhibition of B cell effector function","volume":"17","author":"Sage","year":"2016","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.588315\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T05:06:27Z","timestamp":1603775187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.588315\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2020.588315"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.588315","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"article-number":"588315"}}